Search results
Showing 76 to 90 of 129 results for bacterial infections
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
Early value assessment (EVA) guidance on point-of-care tests for urinary tract infections to improve antimicrobial prescribing.
QuikRead go for C-reactive protein testing in primary care (MIB78)
NICE has developed a medtech innovation briefing (MIB) on the QuikRead go for C-reactive protein testing in primary care
Prevention of recurrence of C3 glomerulopathy post-transplant: eculizumab (ESUOM44)
Summary of the evidence on eculizumab to prevent the recurrence of C3 glomerulopathy post-transplant to inform local NHS planning and decision-making
The MIST Therapy system for the promotion of wound healing (HTG267)
Evidence-based recommendations on the MIST Therapy system for the promotion of wound healing.
Xpert GBS test for the intrapartum detection of group B streptococcus (MIB28)
NICE has developed a medtech innovation briefing (MIB) on Xpert GBS test for the intrapartum detection of group B streptococcus
Alere Afinion CRP for C-reactive protein testing in primary care (MIB81)
NICE has developed a medtech innovation briefing (MIB) on the Alere Afinion CRP for C-reactive protein testing in primary care
This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.
Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)
We have moved HTE2 to become 'antimicrobial resistance guidance'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The guidance itself has not changed. See antimicrobial resistance guidance 2 on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.
This quality standard covers diagnosing and managing atopic eczema in children under 12. It describes high-quality care in priority areas for improvement.
View quality statements for QS44Show all sections
Sections for QS44
- Quality statements
- Quality statement 1: Assessment at diagnosis
- Quality statement 2: Stepped approach to management
- Quality statement 3: Psychological wellbeing and quality of life
- Quality statement 4: Provision of emollients
- Quality statement 5: Referral for specialist dermatological advice
- Quality statement 6: Specialist allergy investigation
- Quality statement 7: Treatment of eczema herpeticum
We have moved HTE1 to become 'antimicrobial resistance guidance'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The guidance itself has not changed. See antimicrobial resistance guidance 1 on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.
NICE has developed a Medtech Innovation Briefing (MIB) on the Versajet II hydrosurgery system
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making
NG50/6 Question Antibiotic resistance in treating spontaneous bacterial peritonitis:- How frequently does antibiotic resistance occur,...
Cabotegravir for preventing HIV-1 in adults and young people (TA1106)
Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.